Entrada Therapeutics, Inc. (TRDA)
NASDAQ: TRDA · Real-Time Price · USD
18.62
+0.85 (4.78%)
Nov 5, 2024, 4:00 PM EST - Market closed
Entrada Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for TRDA stock have an average target of 21.67, with a low estimate of 18 and a high estimate of 25. The average target predicts an increase of 16.38% from the current stock price of 18.62.
Analyst Consensus: Strong Buy
* Price targets were last updated on Aug 26, 2024.
Analyst Ratings
The average analyst rating for TRDA stock from 3 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Jun '24 | Jul '24 | Aug '24 | Sep '24 | Oct '24 | Nov '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 1 | 1 | 2 | 2 | 2 | 2 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 3 | 3 | 3 | 3 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy Reiterates $25 | Buy | Reiterates | $25 | +34.26% | Aug 26, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $18 | Strong Buy | Reiterates | $18 | -3.33% | Aug 14, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $20 → $18 | Strong Buy | Maintains | $20 → $18 | -3.33% | Jun 25, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +7.41% | Mar 18, 2024 |
| Oppenheimer | Oppenheimer | Buy Initiates $22 | Buy | Initiates | $22 | +18.15% | Jan 5, 2024 |
Financial Forecast
Revenue This Year
179.41M
from 129.01M
Increased by 39.06%
Revenue Next Year
50.85M
from 179.41M
Decreased by -71.66%
EPS This Year
0.46
from -0.20
EPS Next Year
-3.52
from 0.46
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 199.3M | 63.0M | 78.8M | ||
| Avg | 179.4M | 50.9M | 65.1M | ||
| Low | 150.7M | 34.3M | 55.3M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 54.5% | -64.9% | 54.9% | ||
| Avg | 39.1% | -71.7% | 28.0% | ||
| Low | 16.8% | -80.9% | 8.7% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.92 | -1.52 | -1.65 | ||
| Avg | 0.46 | -3.52 | -3.34 | ||
| Low | -0.20 | -4.46 | -4.31 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.